A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1730-1738

  Gaudin, Catherine ^a   Kremer, Florence ^a   Angevin, Eric ^a   Scott, Véronique ^a   Triebel, Frédéric ^a,b  

^a Institut Gustave   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 70 2; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; KIDNEY CARCINOMA; MOLECULAR CLONING; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CARCINOMA, RENAL CELL; CLONE CELLS; COS CELLS; DNA PRIMERS; DNA, COMPLEMENTARY; HLA-A2 ANTIGEN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033082486     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Farace, F., E. Angevin, I. Poullion, C. Leboullaire, G. Ferir, D. Elias, B. Escudier, and F. Triebel. 1997. T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines. Int. J. Cancer 71:972.
2. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
3. Kumar, A., F. Farace, C. Gaudin, and F. Triebel. 1996. Clonal T cell expansion induced by interleukin-2 therapy in blood and tumors. J. Clin. Invest. 97:1219.
4. Bernhard, H., J. Karbach, T. Wolfel, P. Busch, S. Storkel, M. Stockle, C. Wolfel, B. Seliger, C. Huber, K. H. M. z. Buschenfelde, and A. Knuth. 1994. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int. J. Cancer 59:837.
5. Brouwenstijn, N., B. Gaugler, K. M. Kruse, C. W. V. d. Spek, A. Mulder, S. Osanto, B. J. V. d. Eynde, and P. I. Schrier. 1996. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Int. J. Cancer 68:177.
6. Alexander, J. P., S. Kudoh, K. A. Melsop, T. A. Hamilton, M. G. Edinger, R. R. Tubbs, D. Sica, L. Tuason, E. Klein, R. M. Bukowski, and J. H. Finke. 1993. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 53:1380.
7. Angevin, E., F. Kremer, C. Gaudin, T. Hercend, and F. Triebel. 1997. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T cell expansion and tumor-specific cytotoxicity. Int. J. Cancer 72:431.
8. Rosenberg, S. A. 1992. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:180.
9. Salter, R. D., A. M. Norment, B. P. Chen, C. Clayberger, A. M. Kresky, D. R. Littman, and P. Parham. 1989. Polymorphism in the α3 domain of HLA-A molecules affects binding to CD8. Nature 338:345.
10. Genevee, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22:1261.
11. Even, J., A. Lim, I. Puisieux, L. Ferradini, P. Y. Dietrich, A. Toubert, T. Hercend, F. Triebel, C. Pannetier, and P. Kourilsky. 1995. T-cell repertoires in healthy and diseased human tissues analyzed by T-cell receptor β-chain CDR3 size determination: evidence for oligoclonal expansions in tumors and inflammatory diseases. Res. Immunol. 146:65.
12. Pannetier, C., M. Cochet, S. Darche, A. Casrouge, M. Zoller, and P. Kourilsky. 1993. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ-line segments. Proc. Natl. Acad. Sci. USA 90:2472.
13. Ennis, P. D., J. Zemmour, R. D. Salter, and P. Parham. 1990. Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc. Natl. Acad. Sci. USA 87:2833.
14. Birnboim, H. C., and J. Doly. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7:1513.
15. Brichard, V., A. V. Pel, T. Wölfel, C. Wölfel, E. D. Plaen, B. Lethé, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.
16. Traversari, C., P. Van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolylic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
17. Nijman, H. W., J. G. Houbiers, M. P. Vierboom, S. H. v. d. Burg, J. W. Drijfhout, J. D'Amaro, P. Kenemans, C. J. Melief, and W. M. Kast. 1993. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1215.
18. Gaudin, C., P. Y. Dietrich, S. Robache, M. Guillard, B. Escudier, M. J. Terrier-Lacombe, A. Kumar, F. Triebel, and A. Caignard. 1995. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res. 55:685.
19. Seed, B. 1987. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 329:840.
20. Milner, C. M., and R. D. Campbell. 1990. Structure and expression of the three MHC-linked HSP70 genes. Immunogenetics 32:242.
21. Wölfel, T. E. Klehmann, C. Muller, K. H. Schutt, and K. H. Meyer zum Buschenfelde. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompalibility leukocyte antigen A2 us a restriction element for three different antigens. J. Exp. Med. 170:797.
22. Kawakami, Y., R. Zakut, S. L. Topalian, H. Stotter, and S. A. Rosenberg. 1992. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J. Immunol. 148:638.
23. Mackensen, A., L. Ferradini, G. Carcelain, F. Triebel, F. Faure, S. Viel, and T. Hercend. 1993. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 53:3569.
24. Eynde, B. V. d., and V. G. Brichard. 1995. New tumor antigens recognized by T cells. Curr. Opin. Immunol. 7:674.
25. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.
26. Coulie, P. G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92:7976.
27. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. D. Plaen, T. Hankeln, K. H. M. z. Buschenfelde, and D. Beach. 1995. A p16ink4a-insensitive CDK4 mutant targeted by cytolytie T lymphocytes in a human melanoma. Science 269:1281.
28. Brandle, D., F, Brasseur, P. Weynants, T. Boon, and B. J. V. d. Eynde. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183:2501.
29. Gaugler, B., N. Brouwenstijn, V. Vantomme, J. P. Szikora, C. W. V. d. Spek, J. J. Patard, T. Boon, P. Schrier, and B. J. V. d. Eynde. 1996. A new gene coding for an antigen recognized by autologous cylolytic T lymphocytes an a human renal carcinoma. Immunogenetics 44:323.
30. Jorgensen, J. L., U. Esser, B. Fazekas de St, Groth, P. A. Reay, and M. M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature 355:224.
31. Puisieux, I., J. Even, C. Pannetier, F. Jotereau, M. Favrot, and P. Kourilsky. 1994. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J. Immunol. 153:2807.
32. Puisieux, I., C. Bain, Y. Merrouche, P. Malacher, P. Kourilsky, J. Even, and M. Favrot. 1996. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma: relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int. J. Cancer 66:201.
33. Caignard, A., P. Y. Dietrich, V. Morand, A. Lim, C. Pannetier, A. M. Leridant, T. Hercend, J. Even, P. Kourilsky, and F. Triebel. 1994. Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. Cancer Res. 54:1.
34. Valteau, D., V. Scott, G. Carcelain, O. Hartmann, B. Escudier, T. Hercend, and F. Triebel. 1996. T-cell receptor repertoire in neuroblastoma patients. Cancer Res. 56:362.
35. Gruen, J. R., and S. M. Weissman. 1997. Evolving views of the major histocompatibility complex. Blood 90:4252.
36. Jarjour, W., A. M. Reed, J. Gauthier, S. Hunt, and J. B. Winfield. 1996. The 8.5-kb PstI allele of the stress protein gene. Hsp70-2: an independent risk factor for systemic lupus erythematosus in African Americans? Hum. Immunol. 45:59.
37. Corzo, D., J. J. Yunis, M. Salazar, J. A. Lieberman, A. Howard, Z. Awdeh, C. A. Alper, and E. J. Yunis. 1995. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86:3835.
38. Milner, C M., and R. D. Campbell. 1992. Polymorphic analysis of the three MHC-linked HSP70 genes. Immunogenetics 36:357.
39. Chouchane, L., S. B. Ahmed, S. Baccouche, and S. Remadi. 1997. Polymorphism in the tumor necrosis factor-α promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80:1489.
40. Zhu, D., D. J. Dix, and E. M. Eddy. 1997. HSP70-2 is required for CDC2 kinase activity in meiosis 1 of mouse spermatocytes. Development 124:3007.
41. Dix, D. J., J. W. Allen, B. W. Collins, C. Mori, N. Nakamura, P. Poorman-Allen, E. H. Goulding, and E. M. Eddy. 1996. Targeted gene disruption of HSP70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc. Natl. Acad. Sci. USA 93:3264.
42. Blachere, N. E., Z. Li, R. Y. CHandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocytes response and tumor immunity. J. Exp. Med. 186:1315.
43. Ciupitu, A. M., M. Petersson, C. L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R. M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685.
44. Fischer, H. P., C. E. Sharrock, and G. S. Panayi. 1992. High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock protein. Eur. J. Immunol. 22:1667.
45. Suzue, K., and R. A. Young. 1996. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156:873.
46. Suzue, K., X. Zhou, H. N. Eisen, and R. A. Young. 1997. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class 1 presentation pathway. Proc. Natl. Acad. Sci. USA 94:13146.
47. Rook, G. A., and J. L. Stanford. 1998. Give us this day our daily germs. Immunol. Today 19:113.